The ASX has closed out a powerful day of trading, with every single sector moving higher to contribute to a new record high ...

The ASX surged to fresh highs on Thursday with Northern Star glittering, but James Hardie, Sonic and Megaport dragged the other way.

ASX held up at lunch with banks flexing, while miners copped a hiding, James Hardie collapsed, CSL kept bleeding billions.

US biotech Response Pharmaceuticals (Nasdaq: RSPN) has unveiled top-line Phase II results for its experimental obesity ...

Results from a Phase II trial (NCT06640972) showed that patients treated with RDX-002 experienced significant reductions in ...

Response is also considering running trials of the weight management drug RDX-002 in combination with GLP-1RA therapies.

Response Pharmaceuticals has shared phase 2 data in post-GLP-1 patients, linking its ex-Sanofi asset to reductions in ...

RDX-002, a novel iMTP inhibitor, showed promising results in a Ph2 study, reducing blood fat and weight regain after GLP-1 ...

Taking weight off with a glucagon-like peptide-1 (GLP-1) receptor agonist and keeping it off once the drug has been discontinued has been a tall order but Response Pharmaceuticals Inc. is seeing ...

Among the prominent players are Intrabio Inc., Niagen Bioscience Inc., and Quince Therapeutics Inc. Typically, A-T is first diagnosed before the age of 5 as children begin to develop an altered gait.

In Malegaon Verdict, Court Rejects "RDX Theory", Flags A Contradiction The court dismissed conflicting theories presented by both agencies as unsupported by credible or consistent evidence ...

7/11 blasts: HC disbelieved recovery of RDX on hyper-technical ground, Maha govt tells SC | Latest News India ...